Please assess the completion status of the following clinical trial:

Trial Title: Phase II Clinical Trial of ITF2357 In Patients With Relapsed/Refractory Multiple Myeloma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Established diagnosis of multiple myeloma according to International Myeloma Working Group diagnostic criteria~2. Age ≥ 18 years~3. Patient relapsed after at least 2 lines of conventional chemotherapy or high dose therapy with autologous or allogeneic stem cell support, and/or for whom no alternative treatments are available/suitable~4. Increasing trend of monoclonal immunoglobulin or Bence-Jones proteinuria through the last 4 consecutive pre-screening measurements, already available in the patient history~5. No chemotherapy or other investigational anticancer therapy for at least 3 weeks before the start of the study~6. Full recovery from previous toxicities~7. ECOG performance status 0-2~8. Adequate bone marrow reserve: absolute neutrophil count ≥ 1000/ml; platelet count ≥ 90000/ml~9. Adequate liver function: total bilirubin within normal institutional limits (PI center); AST(SGOT)/ALT(SGPT) ≤ 2.5 x institutional upper limit of normal (PI center)~10. Adequate renal function: Creatinine ≤ 2.5 mg/dl or creatinine clearance ≥ 50 ml/min~11. Either men or women, accepting to practice effective contraception during the entire study period unless documentation of infertility exists. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should immediately inform her treating physician; in this case ITF 2357 treatment will be promptly discontinued~12. Able to understand and willing to sign the informed consent form.~Exclusion Criteria:~1. Planned autologous or allogeneic bone marrow transplantation within 4 weeks of the initiation of ITF 2357 administration~2. Concurrent use of medicines that would confound the interpretation of toxicities and anti-tumour activity of ITF 2357 (i.e. quinolones, macrolides, 5-HT3 antagonists except for palonosetron,)~3. Clinically significant illness including, but not limited to, the following: active infection, uncontrolled hypertension, symptomatic congestive heart failure, unstable angina pectoris, myocardial infarction within the past 6 months, cardiac arrhythmia (present or documented in the past, of any kind), any other condition (including laboratory abnormalities) that in the opinion of the Investigator places the patient to unacceptable risk for adverse outcome if he/she were to participate in the study~4. Psychiatric illness/social situations that would limit compliance with study medication and protocol requirements~5. Pregnant or lactating women~6. Positive blood tests for HIV, HBV, HCV, active EBV and CMV~7. Diseases related to active viral infections~8. Patients with a marked baseline prolongation of QTc interval (e.g. repeated demonstration of a QTc interval \>440 ms for men and \>450 ms for women)~9. Patients with history of additional risk factors for Torsade de Pointes (e.g. heart failure, family history of Long QT Syndrome).~10. The use of concomitant medications with potential risk of Torsade de Pointes and/or that can prolong QTc interval~    -

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ITF2357 (Type: EXPERIMENTAL): Eligible patients had to be treated with weekly single doses of ITF2357 according to the above mentioned treatment plan.

Based on this trial design, predict the completion outcome and termination type (if applicable).